[Post-schizophrenic depression].
Higuchi H.
Ryoikibetsu Shokogun Shirizu. 2003;(38):46-9.
[Melatonergic antidepressant agomelatine: augmentation of antipsychotic drugs in treatment of post-schizophrenic depression].
Ivanov SV.
Zh Nevrol Psikhiatr Im S S Korsakova. 2024;124(8):5-12. doi: 10.17116/jnevro20241240815.
Treatment of post-psychotic depression in first-episode psychosis. A systematic review.
Bodoano Sánchez I, Mata Agudo A, Guerrero-Jiménez M, Girela Serrano B, Álvarez Gil P, Carrillo de Albornoz Calahorro CM, Gutiérrez-Rojas L.
Nord J Psychiatry. 2023 Feb;77(2):109-117. doi: 10.1080/08039488.2022.2067225. Epub 2022 May 4.
Efficacy and safety of low-dose amisulpride versus olanzapine-fluoxetine combination in post-schizophrenic depression: A randomized controlled trial.
Biswas T, Mishra BR, Maiti R, Padhy SK, Mishra A.
J Psychiatr Res. 2024 May;173:302-308. doi: 10.1016/j.jpsychires.2024.03.048. Epub 2024 Mar 28.
[Post-schizophrenic depression].
Fadda S, Müller C.
Ann Med Psychol (Paris). 1975 Jun;2(1):65-71.
[Depression and schizophrenia].
Smulevich AV.
Zh Nevrol Psikhiatr Im S S Korsakova. 2003;103(4):4-13.
[Clinical and experimental-psychological data of post-schizophrenic depression VG].
Kenchadze VG, Chkoniia ED.
Georgian Med News. 2007 Sep;(150):17-21.
Transcranial magnetic stimulation for treatment resistant depression: six case reports and review.
Krisanaprakornkit T, Paholpak S, Tassaniyom K, Pimpanit V.
J Med Assoc Thai. 2010 May;93(5):580-6.
[Depression in schizophrenia: diagnosis, epidemiology, predisposing factors].
Stamouli S.
Psychiatriki. 2010 Jan;21(1):68-75.
[Basic symptoms in young female patients with depression within the framework of schizophrenia and affective spectrum disorders].
Shishkovskaia TI, Oleichik IV, Baranov PA.
Zh Nevrol Psikhiatr Im S S Korsakova. 2024;124(6):94-100. doi: 10.17116/jnevro202412406194.
